
    
      Approximately 400 eligible subjects will be randomized to one of the following 2 treatment
      arms:

      Investigational Arm:

      Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day
      cycle).

      Control Arm:

      Recommended doses and schedules as per NCCN guidelines (with dose modifications if too
      toxic).

      Eribulin; Capecitabine; Gemcitabine; Vinorelbine
    
  